These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36129834)

  • 1. PARP in colorectal cancer: Molecular mechanisms, immunity, clinical trials, and drug combinations.
    Wu FH; Wei HZ; Deng HY; Xiao GH; Zhang YC
    Neoplasma; 2023 Feb; 70(1):1-14. PubMed ID: 36129834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function.
    Li J; Li Q; Zhang L; Zhang S; Dai Y
    Biomed Pharmacother; 2023 Jan; 157():114028. PubMed ID: 36410122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
    Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
    J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(ADP-Ribose) Polymerase Inhibition Sensitizes Colorectal Cancer-Initiating Cells to Chemotherapy.
    Jarrar A; Lotti F; DeVecchio J; Ferrandon S; Gantt G; Mace A; Karagkounis G; Orloff M; Venere M; Hitomi M; Lathia J; Rich JN; Kalady MF
    Stem Cells; 2019 Jan; 37(1):42-53. PubMed ID: 30353615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP mediated DNA damage response, genomic stability and immune responses.
    Zong C; Zhu T; He J; Huang R; Jia R; Shen J
    Int J Cancer; 2022 Jun; 150(11):1745-1759. PubMed ID: 34952967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
    Rabenau K; Hofstatter E
    Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: A counterbalance between anti-tumor and pro-tumor.
    Yi XF; Gao RL; Sun L; Wu ZX; Zhang SL; Huang LT; Han CB; Ma JT
    Biomed Pharmacother; 2023 Jul; 163():114770. PubMed ID: 37105074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
    Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
    [No Abstract]   [Full Text] [Related]  

  • 9. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers.
    Vilar E; Bartnik CM; Stenzel SL; Raskin L; Ahn J; Moreno V; Mukherjee B; Iniesta MD; Morgan MA; Rennert G; Gruber SB
    Cancer Res; 2011 Apr; 71(7):2632-42. PubMed ID: 21300766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP and PARG inhibitors in cancer treatment.
    Slade D
    Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research progress on the association between environmental pollutants and the resistance mechanism of PARP inhibitors in ovarian cancer.
    Zhou L; Xiang J; He Y
    Environ Sci Pollut Res Int; 2021 Sep; 28(36):49491-49506. PubMed ID: 34370190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving DNA repair synthetic lethality targets in cancer.
    Kulkarni S; Brownlie J; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
    Biosci Rep; 2022 Dec; 42(12):. PubMed ID: 36420962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unravelling the Role of PARP1 in Homeostasis and Tumorigenesis: Implications for Anti-Cancer Therapies and Overcoming Resistance.
    Lovsund T; Mashayekhi F; Fitieh A; Stafford J; Ismail IH
    Cells; 2023 Jul; 12(14):. PubMed ID: 37508568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells.
    Ito S; Murphy CG; Doubrovina E; Jasin M; Moynahan ME
    PLoS One; 2016; 11(7):e0159341. PubMed ID: 27428646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
    Dulaney C; Marcrom S; Stanley J; Yang ES
    Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP inhibitor resistance: the underlying mechanisms and clinical implications.
    Li H; Liu ZY; Wu N; Chen YC; Cheng Q; Wang J
    Mol Cancer; 2020 Jun; 19(1):107. PubMed ID: 32563252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly adenosine diphosphate-ribosylation, a promising target for colorectal cancer treatment.
    Jeong KY; Park M
    World J Gastrointest Oncol; 2021 Jun; 13(6):574-588. PubMed ID: 34163574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review.
    Mehta P; Bothra SJ
    Adv Genet; 2021; 108():35-80. PubMed ID: 34844716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
    Duma N; Gast KC; Choong GM; Leon-Ferre RA; O'Sullivan CC
    Curr Oncol Rep; 2018 Jun; 20(8):63. PubMed ID: 29884921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.